New Orleans, LA, May 16 – Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide® reduces blood pressure in hypertensive patients.
Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide(R) reduces blood pressure in hypertensive patients. The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide(R) Dietary Supplement) II, and
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo.
Progression-free survival was significantly longer in patients who received Alimta compared to those who received placebo, according to preliminary data.
Nearly two-thirds of kidney cancer patients taking Novartis AG's RAD001 had progression of their disease delayed by a year, a significantly better result than in those taking placebo, investigators said.
Lung cancer patients who took Eli Lilly and Co's Alimta after finishing their normal course of chemotherapy lived 40 percent longer without any tumor progression than patients who took a placebo, researchers reported on Thursday.
Dynavax Technologies Corporation (Nasdaq:DVAX) today reported primary endpoint data from a chamber study of TOLAMBA(TM) that showed a measurable clinical benefit, reducing total nasal symptom score (TNSS) by 41% vs. placebo in 253 patients in the intent-to-treat population (p=0.09) and by 51% vs. placebo in 222 patients in the per-protocol population (p=0.053). Statistical significance on the
An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
Members
Area
Top
Downloads 
Placebo MP3 albums: 
RSS feed
View comments
Hide comments
Browse
Genres 
